Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP).
Sakata Y, Saito G, Sakata S, Oya Y, Tamiya M, Suzuki H, Shibaki R, Okada A, Yokoyama T, Matsumoto H, Otsuki T, Sato Y, Junji U, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T.
Sakata Y, et al. Among authors: tamiya m.
Lung Cancer. 2023 Dec;186:107426. doi: 10.1016/j.lungcan.2023.107426. Epub 2023 Nov 19.
Lung Cancer. 2023.
PMID: 37992594